Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on OmniAb. The associated price target remains the same with $11.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight OmniAb’s strategic advancements and financial stability. One of the key reasons is the launch of the xPloration Partner Access Program, which has begun generating revenue for the company. This program leverages a high-throughput single B-cell screening instrument that integrates machine learning and artificial intelligence, offering a significant improvement over traditional methods. The platform’s ability to process millions of single B-cells and recover thousands of antibody variants in a short time frame positions it as a superior alternative in the market.
Additionally, the company’s financial health is supported by a substantial cash reserve of $41.6 million, which is expected to sustain ongoing operations. OmniAb’s momentum in expanding its partner programs is also noteworthy, with 100 active partners and 381 active programs by the end of the second quarter of 2025. These developments suggest a strong potential for steady revenue growth, making OmniAb an attractive investment opportunity according to Pantginis.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $4.00 price target.